Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells

Ramakumar Tummala, Wei Lou, Allen C Gao, Nagalakshmi Nadiminty

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Prostate cancer remains dependent on androgen receptor signaling even after castration. Aberrant androgen receptor signaling in castration-resistant prostate cancer is mediated by mechanisms such as alterations in the androgen receptor and activation of interacting signaling pathways. Clinical evidence confirms that resistance to the next-generation antiandrogen, enzalutamide, may be mediated to a large extent by alternative splicing of the androgen receptor to generate constitutively active splice variants such as AR-V7. The splice variants AR-V7 and ARv567es have been implicated in the resistance to not only enzalutamide, but also to abiraterone and other conventional therapeutics such as taxanes. Numerous studies, including ours, suggest that splicing factors such as hnRNPA1 promote the generation of AR-V7, thus contributing to enzalutamide resistance in prostate cancer cells. In the present study, we discovered that quercetin, a naturally occurring polyphenolic compound, reduces the expression of hnRNPA1, and consequently, that of AR-V7. The suppression of AR-V7 by quercetin resensitizes enzalutamide-resistant prostate cancer cells to treatment with enzalutamide. Our results indicate that quercetin downregulates hnRNPA1 expression, downregulates the expression of AR-V7, antagonizes androgen receptor signaling, and resensitizes enzalutamide-resistant prostate cancer cells to enzalutamide treatment in vivo in mouse xenografts. These findings demonstrate that suppressing the alternative splicing of the androgen receptor may have important implications in overcoming the resistance to next-generation antiandrogen therapy.

Original languageEnglish (US)
Pages (from-to)2770-2779
Number of pages10
JournalMolecular Cancer Therapeutics
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Quercetin
Androgen Receptors
Prostatic Neoplasms
Androgen Antagonists
Castration
Alternative Splicing
Down-Regulation
Taxoids
MDV 3100
Heterografts
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells. / Tummala, Ramakumar; Lou, Wei; Gao, Allen C; Nadiminty, Nagalakshmi.

In: Molecular Cancer Therapeutics, Vol. 16, No. 12, 01.12.2017, p. 2770-2779.

Research output: Contribution to journalArticle

Tummala, Ramakumar ; Lou, Wei ; Gao, Allen C ; Nadiminty, Nagalakshmi. / Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 12. pp. 2770-2779.
@article{8853ce8e0104418da0e44720ff8c3068,
title = "Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells",
abstract = "Prostate cancer remains dependent on androgen receptor signaling even after castration. Aberrant androgen receptor signaling in castration-resistant prostate cancer is mediated by mechanisms such as alterations in the androgen receptor and activation of interacting signaling pathways. Clinical evidence confirms that resistance to the next-generation antiandrogen, enzalutamide, may be mediated to a large extent by alternative splicing of the androgen receptor to generate constitutively active splice variants such as AR-V7. The splice variants AR-V7 and ARv567es have been implicated in the resistance to not only enzalutamide, but also to abiraterone and other conventional therapeutics such as taxanes. Numerous studies, including ours, suggest that splicing factors such as hnRNPA1 promote the generation of AR-V7, thus contributing to enzalutamide resistance in prostate cancer cells. In the present study, we discovered that quercetin, a naturally occurring polyphenolic compound, reduces the expression of hnRNPA1, and consequently, that of AR-V7. The suppression of AR-V7 by quercetin resensitizes enzalutamide-resistant prostate cancer cells to treatment with enzalutamide. Our results indicate that quercetin downregulates hnRNPA1 expression, downregulates the expression of AR-V7, antagonizes androgen receptor signaling, and resensitizes enzalutamide-resistant prostate cancer cells to enzalutamide treatment in vivo in mouse xenografts. These findings demonstrate that suppressing the alternative splicing of the androgen receptor may have important implications in overcoming the resistance to next-generation antiandrogen therapy.",
author = "Ramakumar Tummala and Wei Lou and Gao, {Allen C} and Nagalakshmi Nadiminty",
year = "2017",
month = "12",
day = "1",
doi = "10.1158/1535-7163.MCT-17-0030",
language = "English (US)",
volume = "16",
pages = "2770--2779",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells

AU - Tummala, Ramakumar

AU - Lou, Wei

AU - Gao, Allen C

AU - Nadiminty, Nagalakshmi

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Prostate cancer remains dependent on androgen receptor signaling even after castration. Aberrant androgen receptor signaling in castration-resistant prostate cancer is mediated by mechanisms such as alterations in the androgen receptor and activation of interacting signaling pathways. Clinical evidence confirms that resistance to the next-generation antiandrogen, enzalutamide, may be mediated to a large extent by alternative splicing of the androgen receptor to generate constitutively active splice variants such as AR-V7. The splice variants AR-V7 and ARv567es have been implicated in the resistance to not only enzalutamide, but also to abiraterone and other conventional therapeutics such as taxanes. Numerous studies, including ours, suggest that splicing factors such as hnRNPA1 promote the generation of AR-V7, thus contributing to enzalutamide resistance in prostate cancer cells. In the present study, we discovered that quercetin, a naturally occurring polyphenolic compound, reduces the expression of hnRNPA1, and consequently, that of AR-V7. The suppression of AR-V7 by quercetin resensitizes enzalutamide-resistant prostate cancer cells to treatment with enzalutamide. Our results indicate that quercetin downregulates hnRNPA1 expression, downregulates the expression of AR-V7, antagonizes androgen receptor signaling, and resensitizes enzalutamide-resistant prostate cancer cells to enzalutamide treatment in vivo in mouse xenografts. These findings demonstrate that suppressing the alternative splicing of the androgen receptor may have important implications in overcoming the resistance to next-generation antiandrogen therapy.

AB - Prostate cancer remains dependent on androgen receptor signaling even after castration. Aberrant androgen receptor signaling in castration-resistant prostate cancer is mediated by mechanisms such as alterations in the androgen receptor and activation of interacting signaling pathways. Clinical evidence confirms that resistance to the next-generation antiandrogen, enzalutamide, may be mediated to a large extent by alternative splicing of the androgen receptor to generate constitutively active splice variants such as AR-V7. The splice variants AR-V7 and ARv567es have been implicated in the resistance to not only enzalutamide, but also to abiraterone and other conventional therapeutics such as taxanes. Numerous studies, including ours, suggest that splicing factors such as hnRNPA1 promote the generation of AR-V7, thus contributing to enzalutamide resistance in prostate cancer cells. In the present study, we discovered that quercetin, a naturally occurring polyphenolic compound, reduces the expression of hnRNPA1, and consequently, that of AR-V7. The suppression of AR-V7 by quercetin resensitizes enzalutamide-resistant prostate cancer cells to treatment with enzalutamide. Our results indicate that quercetin downregulates hnRNPA1 expression, downregulates the expression of AR-V7, antagonizes androgen receptor signaling, and resensitizes enzalutamide-resistant prostate cancer cells to enzalutamide treatment in vivo in mouse xenografts. These findings demonstrate that suppressing the alternative splicing of the androgen receptor may have important implications in overcoming the resistance to next-generation antiandrogen therapy.

UR - http://www.scopus.com/inward/record.url?scp=85032206169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032206169&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0030

DO - 10.1158/1535-7163.MCT-17-0030

M3 - Article

C2 - 28729398

AN - SCOPUS:85032206169

VL - 16

SP - 2770

EP - 2779

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -